Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

House Oversight Committee Starts Investigating EpiPen Price Hikes; Third Capitol Hill Panel to Dig into Mylan’s Pricing

Capitol Building flagWashington, DC, August 30, 2016 — Catherine Ho reports in The Washington Post that the U.S. House Oversight and Government Reform Committee has launched an investigation into drug maker Mylan, which is facing intense public and political scrutiny for raising the price of its lifesaving EpiPen allergy injection.

The price of an EpiPen two-pack has risen from less than $100 in 2007, the year Mylan acquired the device, to $608 today.

The House Oversight Committee is the third congressional committee to press Mylan on its pricing practices.  

Last week, leaders of the Senate Judiciary Committee and Senate Special Committee on Aging sent similar letters to Mylan, requesting information about how the company determined the price of EpiPens.

The committee’s Republican chairman, Jason Chaffetz (Utah), and its ranking Democrat, Elijah E. Cummings (Md.), on Monday sent a letter to Mylan chief executive Heather Bresch requesting detailed information and communications regarding the company’s pricing of the EpiPen.

The committee’s Monday letter asks Mylan to provide a briefing by Sept. 6 that would not be public and would entail conversations between Mylan representatives and committee representatives.

The letter also asks Mylan to provide documents by Sept. 12 about its profits from EpiPen sales, lobbying disclosure forms dating to 2007 and copies of contracts regarding the manufacture and distribution of EpiPens.

Since the outcry over the EpiPen exploded last week, Mylan has offered two responses — it initially announced it would offer coupons to some consumers.

Then on Monday morning the company announced it will come out with a generic version of the product at half the cost.

Both steps seem to be falling short with lawmakers.

For Ho’s full story, click here.